0 0 0.0131278538812785 0.0102739726027397 0.0142465753424658 0.00114155251141553 0.00342465753424658 0.0184817351598174
Sign Up Today X
Thanks for submitting the form.
Stockreport

UPDATE 1-Regeneron misses profit estimates on weaker Eylea and Dupixent sales [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
estimates for first-quarter profit on Thursday due to softer sales of its blockbuster eye drug Eylea and its eczema treatment, Dupixent. Excluding items, the company reported a profit of $9.55 per share for the quarter, compared with analysts' estimates of $10.09 per share, according to LSEG data. Regeneron has been looking to switch Eylea patients to the high-dose version as the eye drug, which has long been its cash cow, faces the threat of biosimilars and fierce competition from rivals including Roche's Vabysmo. Sales of Eylea, jointly developed with Bayer AG , was $1.40 billion in the reported quarter, including $200 million from the higher, 8 milligram dose version of the drug. The high-dose Eylea sales figure was in line with estimates from JPM analysts. Analysts were expecting $1.86 billion in total Eylea sales, according to LSEG estimates. Regeneron posted total revenue of $3.15 billion, falling short of estimates of $3.22 billion. (Reporting by Sriparna Roy in Ben [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

UPDATE 1-Regeneron misses profit estimates on weaker Eylea and Dupixent sales [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
estimates for first-quarter profit on Thursday due to softer sales of its blockbuster eye drug Eylea and its eczema treatment, Dupixent. Excluding items, the company reported a profit of $9.55 per share for the quarter, compared with analysts' estimates of $10.09 per share, according to LSEG data. Regeneron has been looking to switch Eylea patients to the high-dose version as the eye drug, which has long been its cash cow, faces the threat of biosimilars and fierce competition from rivals including Roche's Vabysmo. Sales of Eylea, jointly developed with Bayer AG , was $1.40 billion in the reported quarter, including $200 million from the higher, 8 milligram dose version of the drug. The high-dose Eylea sales figure was in line with estimates from JPM analysts. Analysts were expecting $1.86 billion in total Eylea sales, according to LSEG estimates. Regeneron posted total revenue of $3.15 billion, falling short of estimates of $3.22 billion. (Reporting by Sriparna Roy in Ben [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS